辅活化剂
核受体辅活化子3
核受体辅活化子2
核受体辅活化子1
生物
雌激素受体α
结合位点
生物物理学
核受体
肽
兴奋剂
雌激素受体
受体
生物化学
细胞生物学
转录因子
遗传学
基因
癌症
乳腺癌
作者
Andrew K. Shiau,Danielle Barstad,Paula M. Loria,Lin Cheng,Peter J. Kushner,David A. Agard,Geoffrey L. Greene
出处
期刊:Cell
[Cell Press]
日期:1998-12-01
卷期号:95 (7): 927-937
被引量:3067
标识
DOI:10.1016/s0092-8674(00)81717-1
摘要
Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators. Receptor agonists promote coactivator binding, and antagonists block coactivator binding. Here we report the crystal structure of the human estrogen receptor alpha (hER alpha) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hER alpha LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT). In the DES-LBD-peptide complex, the peptide binds as a short alpha helix to a hydrophobic groove on the surface of the LBD. In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD. These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.
科研通智能强力驱动
Strongly Powered by AbleSci AI